492 related articles for article (PubMed ID: 16172461)
21. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.
Olivier M; Langerød A; Carrieri P; Bergh J; Klaar S; Eyfjord J; Theillet C; Rodriguez C; Lidereau R; Bièche I; Varley J; Bignon Y; Uhrhammer N; Winqvist R; Jukkola-Vuorinen A; Niederacher D; Kato S; Ishioka C; Hainaut P; Børresen-Dale AL
Clin Cancer Res; 2006 Feb; 12(4):1157-67. PubMed ID: 16489069
[TBL] [Abstract][Full Text] [Related]
22. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
Ichikawa W; Ooyama A; Toda E; Sugimoto Y; Oka T; Takahashi T; Shimizu M; Sasaki Y; Hirayama R
Cancer Chemother Pharmacol; 2006 Dec; 58(6):794-801. PubMed ID: 16528528
[TBL] [Abstract][Full Text] [Related]
23. The role of combined allelic imbalance and mutations of p53 in tumor progression and survival following surgery for colorectal carcinoma.
Lagerstedt KK; Kressner U; Lönnroth C; Nordgren S; Lundholm K
Int J Oncol; 2005 Dec; 27(6):1707-15. PubMed ID: 16273227
[TBL] [Abstract][Full Text] [Related]
24. Clinical value of mitochondrial mutations in colorectal cancer.
Lièvre A; Chapusot C; Bouvier AM; Zinzindohoué F; Piard F; Roignot P; Arnould L; Beaune P; Faivre J; Laurent-Puig P
J Clin Oncol; 2005 May; 23(15):3517-25. PubMed ID: 15908662
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer.
Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Verlind E; Hermans J; Poppema S; Buys CH; Plukker JT
Dis Colon Rectum; 2001 Mar; 44(3):358-63. PubMed ID: 11289281
[TBL] [Abstract][Full Text] [Related]
26. Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer.
Catalano T; Curia MC; Aceto G; Verginelli F; Cascinu S; Cama A; Mariani-Costantini R; Teti D; Battista P
Oncol Rep; 2005 Sep; 14(3):625-31. PubMed ID: 16077965
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.
Powell B; Soong R; Iacopetta B; Seshadri R; Smith DR
Clin Cancer Res; 2000 Feb; 6(2):443-51. PubMed ID: 10690522
[TBL] [Abstract][Full Text] [Related]
29. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
[TBL] [Abstract][Full Text] [Related]
30. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
31. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
[TBL] [Abstract][Full Text] [Related]
32. High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform.
Lilleberg SL; Durocher J; Sanders C; Walters K; Culver K
Ann N Y Acad Sci; 2004 Jun; 1022():250-6. PubMed ID: 15251969
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical and mutational analyses of beta-catenin, Ki-ras, and p53 in two subtypes of colorectal mucinous carcinoma.
Ikeda S; Shimizu Y; Fujimori M; Ishizaki Y; Kurihara T; Ojima Y; Okajima M; Asahara T
Clin Cancer Res; 2003 Nov; 9(15):5660-5. PubMed ID: 14654549
[TBL] [Abstract][Full Text] [Related]
34. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer.
Arango D; Laiho P; Kokko A; Alhopuro P; Sammalkorpi H; Salovaara R; Nicorici D; Hautaniemi S; Alazzouzi H; Mecklin JP; Järvinen H; Hemminki A; Astola J; Schwartz S; Aaltonen LA
Gastroenterology; 2005 Sep; 129(3):874-84. PubMed ID: 16143127
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
[TBL] [Abstract][Full Text] [Related]
36. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival.
Børresen-Dale AL; Lothe RA; Meling GI; Hainaut P; Rognum TO; Skovlund E
Clin Cancer Res; 1998 Jan; 4(1):203-10. PubMed ID: 9516972
[TBL] [Abstract][Full Text] [Related]
37. LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer.
Kyndi M; Alsner J; Hansen LL; Sørensen FB; Overgaard J
Acta Oncol; 2006; 45(5):602-9. PubMed ID: 16864176
[TBL] [Abstract][Full Text] [Related]
38. Indication and efficacy of adjuvant chemotherapy with oral fluoropyrimidines for dukes' B colorectal cancer.
Yoshimatsu K; Umehara A; Ishibashi K; Yokomizo H; Yoshida K; Fujimoto T; Watanabe K; Ogawa K
Anticancer Res; 2006; 26(4B):3089-93. PubMed ID: 16886639
[TBL] [Abstract][Full Text] [Related]
39. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
40. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma.
Russo A; Corsale S; Agnese V; Macaluso M; Cascio S; Bruno L; Surmacz E; Dardanoni G; Valerio MR; Vieni S; Restivo S; Fulfaro F; Tomasino RM; Gebbia N; Bazan V
J Cell Physiol; 2006 Jan; 206(1):181-8. PubMed ID: 15965904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
